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ABSTRACT
Objective To determine the loss to follow- up (LTFU) rates 
at different healthcare levels after antiretroviral therapy 
(ART) services decentralisation among ART patients who 
initiated ART between 2004 and 2017 using the competing 
risk model in addition to the Kaplan- Meier and Cox 
regressions analysis.
Design A retrospective cohort study.
Setting The study was done in Zimbabwe using a 
nationwide routinely collected HIV patient- level data from 
various health levels of care facilities compiled through the 
electronic patient management system (ePMS).
Participants We analysed 390 771 participants aged 15 
years and above from 538 health facilities.
Outcomes The primary endpoint was LTFU defined as a 
failure of a patient to report for drug refill for at least 90 
days from last appointment date or if the patient missed 
the next scheduled visit date and never showed up again. 
Mortality was considered a secondary outcome if a patient 
was reported to have died.
Results The total exposure time contributed was 1 
544 468 person- years. LTFU rate was 5.75 (95% CI 
5.71 to 5.78) per 100 person- years. Adjustment for the 
competing event independently increased LTFU rate 
ratio in provincial and referral (adjusted sub- HRs (AsHR) 
1.22; 95% CI 1.18 to 1.26) and district and mission 
(AsHR 1.47; 95% CI 1.45 to 1.50) hospitals (reference: 
primary healthcare); in urban sites (AsHR 1.61; 95% CI 
1.59 to 1.63) (reference: rural); and among adolescence 
and young adults (15–24 years) group (AsHR 1.19; 
95% CI 1.16 to 1.21) (reference: 35–44 years). We also 
detected overwhelming association between LTFU and 
tuberculosis- infected patients (AsHR 1.53; 95% CI 1.45 
to 1.62) (reference: no tuberculosis).
Conclusions We have observed considerable findings 
that ‘leakages’ (LTFU) within the ART treatment cascade 
persist even after the decentralisation of health services. 
Risk factors for LTFU reflect those found in sub- Saharan 
African studies. Interventions that retain patients in care 
by minimising any ‘leakages’ along the treatment cascade 
are essential in attaining the 90–90–90 UNAIDS fast- track 
targets.
INTRODUCTION
Globally, remarkable progress has been 
made on the treatment of HIV- infected 
people using antiretroviral therapy (ART), 
particularly in sub- Saharan Africa (SSA).1 In 
Zimbabwe, the ART programme is a compre-
hensive care and support package aiming to 
slow disease progression,2 improve survival 
and quality of life3 and minimise HIV trans-
mission by reducing the viral load. There-
fore, it is imperative to monitor individuals 
on ART to ensure treatment efficacy, support 
adherence and identify treatment failure and 
resistance.
Strengths and limitations of this study
 ► The analysis is based on a huge national routine-
ly collected individual- level dataset that has a long 
follow- up period making our findings generalisable 
to the patients with HIV on antiretroviral therapy in 
Zimbabwe.
 ► This study fitted a competing risk model based on 
the cumulative incidence function to explore the as-
sociation between selected covariates and the abso-
lute risk, which is an essential modelling approach 
for medical decision making so that appropriate 
subpopulation interventions can be implemented.
 ► Variable selection of the numerous independent 
factors was performed using the regularisation 
(shrinkage) lasso regression technique alongside 
the stepwise section methods.
 ► Important factors known to influence LTFU like CD4 
cell counts and viral load were not accounted for in 
the model due to the high percentage of missing-
ness, and the independent factors adjusted for were 
not time dependent.
 ► This study has a possibility of participant selection 
bias since only participants enrolled in health facil-
ities linked to the electronic patients’ management 
database were used in the analysis.
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At the national level, aggregated health facility data 
are usually used for monitoring the ART programme. 
However, there is an inherent difficulty in using aggre-
gated data to make statistical inferences about individual- 
level outcomes. This promoted the increasing use of 
patient- level data worldwide to assess the impact of the 
ART programme.4–8 With efforts to achieve zero HIV 
incidences by 2030, the 90–90–90 UNAIDS targets were 
launched, whereby 90% of the people living with HIV 
(PLWHIV) should know their status, 90% of those diag-
nosed should be initiated on ART and 90% of those on 
ART should achieve viral suppression.9 In Zimbabwe, 
strides have been made towards achieving these targets; 
however, limitations exist. For instance, in Zimbabwe, 
only 73% of PLWHIV who are on ART have achieved 
viral suppression.10 To improve the proportion of those 
who achieve viral suppression, it is crucial to come up 
with broad efforts that minimise long- term ART attrition 
due to loss to follow- up (LTFU), mortality, drop- outs and 
withdrawals.
In Zimbabwe, the health service delivery can be cate-
gorised into four levels of care, namely the primary, 
secondary, tertiary and quaternary.11 The primary care 
consists of clinics and facilities offering basic preventive 
and curative services. Majority of these primary health-
care (PHC) facilities are in the rural areas, and health 
problems beyond the scope of these facilities are referred 
to the secondary healthcare centres, which are mainly the 
district and mission hospitals. In the secondary care cate-
gory, private and company health facilities may fit in if 
they can handle emergency services as the district hospi-
tals. The tertiary care consists of the provincial hospitals 
that received referral patients from the district hospitals.12 
The quaternary care is the last referral care level that 
received patients from provincial hospitals. These facil-
ities are mainly in the two largest cities in Zimbabwe.12 
The quaternary healthcare offers much more advanced 
healthcare; hence, there is modern equipment, medical 
specialists and pharmaceutical, which could be missing in 
the lower levels of care.11
The ART services were initially centralised at the higher 
levels of care—quaternary and tertiary healthcare facili-
ties—normally situated in urban areas. This means rural 
residents and poorer people were less likely to access 
HIV testing, care and treatment due to transport cost. 
In 2010/2011, one of the strategies to mitigate the trans-
port barrier was the decentralisation of ART services to 
lower levels of care.13 These devolved care models were 
implemented in Zimbabwe to improve patients’ access 
to HIV care, ART adherence and retention in care of 
PLWHIV. The impact of HIV care and ART decentral-
isation has been well documented in the SSA region.14 
Understanding ART retention patterns after the imple-
mentation of decentralised care is vital to guide the ART 
programme and policy as well as reflecting on the gaps 
that may contribute to the poor viral suppression. LTFU 
is one of the main threats to patient retention and may 
persist even after the decentralisation of ART services. 
This may be due to social (stigmatisation, social depri-
vation and health literacy issues) and individual factors 
(perception and misconceptions over ART benefits) that 
still hinder retention in care.15
This study aims to determine LTFU rates at different 
healthcare levels after ART services decentralisation 
among ART patients who initiated ART between 2004 
and 2017. The study period covers the pre- ART and 
post- ART decentralisation period to get an overall picture 
of the LTFU patterns over time. The LTFU rates were 
compared between the different healthcare facility types 
(PHC, district/mission and provincial/referral hospitals) 
in Zimbabwe using routinely collected patients- level data 
from the Zimbabwe national ART database. We further 
adjusted for the individual- level demographic and clinical 
characteristics as predisposing or independent factors 
for LTFU using a statistical model that adjusted for the 
competing risk (CR) of mortality on the LTFU outcome.
METHODS
Study population
This study was conducted in Zimbabwe, a landlocked 
country in SSA with roughly 1.4 million PLWHIV. The 
HIV prevalence dropped from 25% in 2004 to 13.7% in 
2017 among adults.10 16 Individual patients aged 15 years 
and above, who initiated ART between 1 January 2004 
and 31 December 2017, were eligible for this analysis. A 
full description of how the final sample size was achieved 
is illustrated in figure 1.
Study design and data sources
This study was a secondary data analysis from a retro-
spective cohort study of routinely collected patient data 
from the Zimbabwe national ART programme. The 
data came from the national ART programme, which 
started in 2004. The ART sites expanded from 5 health 
facilities in 2004 to 1566 by 2017.10 17 Treatment guide-
lines followed WHO recommendations; hence, the ART 
eligibility criteria and treatment regimens changed over 
time. The initial regimen for an ART- naïve patient is the 
first- line ART, a combination of two nucleoside reverse 
transcriptase inhibitors (NRTIs), the first drug that can 
be zidovudine, tenofovir (TDF) (the most common) or 
stavudine (D4T) and the second drug is mainly lami-
vudine (3TC), and one non- NRTI that can either be 
nevirapine (NVP) or efavirenz (EFV). Majority of the 
participants were receiving three- drug combination 
therapy of TDF+3TC+EFV therapy as the first- line treat-
ment. Once the patient experienced treatment failure 
or intolerance, switch to second- line ART (a three- drug 
combination of protease inhibitor and two NRTIs) can 
be made.18
Monitoring and evaluation system
The monitoring and evaluation system of the ART 
programme in Zimbabwe has been described elsewhere.19 
Briefly, since the inception of ART, all patient monitoring 
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records had been collected manually using a paper- based 
system and kept at the health facility where the patient 
is registered. Since 2012, the paper- based system was 
no longer functioning properly due to high volumes of 
ART patients.10 This upsurge in patients’ volumes began 
to affect the accurate ART monitoring and reporting 
process as the paper- based system could not cope. 
Moreover, the paper- based system translated into huge 
workloads and became strenuous to the already overbur-
dened health workers. As a result, the electronic patient 
management system (ePMS) was launched in 2012. The 
ePMS increased efficiency and effective management 
of ART patients through improving follow- ups to subse-
quently increase ART adherence.19 The ePMS provided 
a platform to compile quality patient- level data to accu-
rately make forecast and evaluate the ART intervention, 
enabling a more effective programme.10
The ePMS was rolled out in systematic phased approach 
with priority given to those HIV sites with high volumes 
of patients with HIV at the same time maintaining a 
good representation of the four healthcare levels in the 
country.19 From the ePMS Strategic Plan document, 
the first phase target was 83 sites in 2013 comprising of 
central, provincial and district hospitals that covered 
approximately 61% of ART patients nationwide. Addi-
tional 267 city polyclinics, rural/large mission hospitals 
sites were included to make a total of 350 sites by the 
end of 2014.19 The last phase included 184 static ART 
follow- up sites to bring the total to 534 sites by the end of 
2017. By the end of 2018, there were 622 sites with a func-
tional ePMS with the inclusion of private hospitals, which 
meant that approximately 95% of all patients receiving 
ART were linked to the ePMS database.10
The final database of the ePMS has patients’ information 
from all levels of care (quaternary, tertiary, secondary and 
primary healthcare levels). It, therefore, reflects the overall 
ART management services in the country, although the 
database includes all HIV- related data. At enrolment, the 
patient’s demographic data are captured. At each subse-
quent clinic visit, information on ART regimen type, clinical 
information, laboratory investigations and physical exam-
ination is captured. Outcomes are assessed and captured 
as death, LTFU, transfer- out to another health facility or 
alive and active on treatment. Already existing patient’s 
information prior to 2012 from the paper- based system was 
retrospectively transcribed into the electronic database at 
each clinic, and all subsequent clinic visits were recorded 
prospectively with a real- time entry of patient records.
Figure 1 Flow chart of the inclusion criteria for analyses of adult ART patients enrolled in Zimbabwe ART Programme followed 
up between 2004 and 2017. ART, antiretroviral therapy; ePMS, electronic patient management system.
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The introduction of the ePMS for monitoring patients 
with HIV in 2012 has provided a platform for huge data 
repository in the country that may be used to answer some 
of the public health questions on the HIV aspects using 
statistical models. Moreover, the ePMS platform provides 
readily available data archiving for robust statistical anal-
ysis approaches to guide evidence- based decision making 
and programme interventions planning at patients level 
while eliminating the aggregated data. Therefore, this 
rich, huge patient- level database was of preference and 
suitable to answer our study objective.
Study endpoints
The primary endpoint was LTFU defined as a failure 
of a patient to report for drug replenishment within 90 
days from last appointment date or if the patient missed 
the next scheduled visit date and never showed up 
again. Patients, who returned after having been LTFU, 
were classified as alive and active on treatment. We also 
consider the mortality outcome as a competing event of 
LTFU if a patient was reported to have died.
Data analysis methods
Descriptive summaries were reported as frequencies 
and proportions stratified by health facility type. The 
pattern of LTFU was explored by calendar year. Inci-
dence rates were calculated from the ART initiation 
date to outcome occurrence date on a quarterly time 
scale. Kaplan- Meier non- parametric curves (equations 
1–4 in online supplemental appendix) were used to 
describe the probability of LTFU over time stratified 
by selected covariates. The log- rank test was used to 
assess the equality of these patient retention probabil-
ities. Estimated hazard rates (HRs) (equations 5–9 in 
online supplemental appendix) were reported as per 
100 person- years.
Important variable selection was done using the lasso 
regression regularisation technique. Variable selection 
sensitivity analysis was done using the subset selection 
techniques (best subset selection, stepwise forward vari-
able selection and stepwise backward variable selection 
methods). All these methods yield the same indepen-
dent factors considered in the seven different multiple 
adjusted time- to- event models fitted (figure 2). The base-
line predictors used for adjustment were all categorical, 
namely: health facility type, degree of urbanisation of the 
health facility (rural/urban), age groups (15–24, 25–34, 
35–44 and 45 and above), tuberculosis status (positive/
negative), body functional status—which is the patient’s 
ability to perform normal daily activities expected for 
the well- being of an individual—(working body, ambu-
latory body and bed- ridden body), WHO clinical stages 
(stage 1, II, III and IV), ART enrolment calendar period 
(2004–2007; 2008–2011; 2012–2014; and 2015–2017) 
and regimen type (D4T, AZT or TDF based combination 
Figure 2 Schematic illustration of the variable of importance selection steps and subsequent models fitted for sensitivity 
analysis of the results.
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therapy). The stratification of the health facility type 
into primary healthcare, district/mission hospitals and 
provincial/referral hospitals was based on the level of 
care classification of the corresponding health facility an 
individual was enrolled in, and the grouping of the health 
facilities was based on the patients’ care similarities. For 
those individuals who had moved from one health facility 
to the other during the study period covered, the last 
recorded health facility site was considered for this anal-
ysis. Therefore, the health level of care classification was 
mutually exclusive as one individual was assigned to the 
last captured health facility.
The standard Cox regression model defined in equa-
tions 10–12 in the online supplemental appendix is 
normally used for a time- to- event analysis; however, this 
method may give biased estimates in the presence of 
competing events. We fitted the CR model of mortality on 
LTFU through the cumulative incidence function defined 
in equations 13–18 in online supplemental appendix.20 
CR analysis assumes that patients are exposed to at least 
two risks (mortality and LTFU). One of the events is of 
interest (LTFU), while the other is a competing event 
(mortality) that inhibits the outcome of interest from 
occurring. The competing events may not be indepen-
dent, and the baseline hazard may differ between them. 
The covariates used were time independent; however, 
we adjusted for time to take into account the period the 
country experienced an economic turmoil around 2008, 
which resulted in a mass withdrawal of health personnel 
in the public sectors and an increased scarcity of vital 
medical supplies in health system including HIV medica-
tion.21 22 The adjusted sub- HRs (AsHR) for covariates on 
LTFU were reported with 95% CIs. We censored on 31 
December 2017 for those who had not experienced the 
event of interest and at the last observed date for those 
who had transferred to other health facilities.
We performed a sensitivity analysis of our key findings 
through multiple imputations of the missing explanatory 
covariates using Rubin’s method, which assumes that the 
data are missing at random.23 We compared imputed 
data and the complete case data estimates based on the 
maximum likelihood estimation (MLE) perspective for 
both the Cox proportional hazard and Gombertz para-
metric models. Within the Gombertz parametric models, 
estimates from the Bayesian estimation (BE) and MLE 
were compared.24 We assumed non- informative normal 
priors for all unknown parameters to be estimated with a 
mean of zero and variance of 100 or precision of 0.001 for 
the parametric Bayesian model. We fitted a parametric 
Weibull model with random effects to account for any 
individual heterogeneity.25 Model comparison between 
BE and MLE was done using the Akaike’s information 
criterion (AIC), Bayesian information criterion (BIC) 
and deviance information criterion. In contrast, model 
comparison between complete case analysis and imputed 
data analysis was done using the precision of the CI for 
the estimates. All data management and analysis were 
performed using Stata V.15.1.26
Patient and public involvement
This study acknowledges the importance of patients and 
public involvement in research studies; however, this 
research was done without patient involvement in all 
research stages since it was secondary data analysis.
Ethical approval
Since this study was secondary data analysis, we did not 
have direct contact with the participants. We received 
only anonymised data for analyses.
RESULTS
Descriptive analysis
At the end of study, 268 896 (68.81%) patients were alive, 
18 328 (4.7%) had died, 88 744 (22.71%) were LTFU 
and 14 803 (3.79%) had transferred out from the initial 
health facility another health facility. Over 1 544 468 
person- years of ART, mortality and LTFU rates were 1.19 
(95% CI 1.17 to 1.20) and 5.75 (95% CI 5.71 to 5.78) per 
100 person- years, respectively. The quarterly trend anal-
ysis graph of LTFU over time showed a general increase in 
LTFU over time with significant peaks in 2012, 2014 and 
2016 (figure 3).
The descriptive characteristics of 390 771 patients from 
538 health facilities are presented in table 1. The study 
participants were enrolled at PHC (45.1%), districts/
mission (49.2%) or provincial/referral (5.7%) hospi-
tals. Most patients were enrolled in rural health facilities 
(66.52%). At ART initiation, the majority of the patients 
were female 255 844 (65.47%), the mean (SD) age was 
37.5 (10.2) years and only 6.44% (n=25, 143) patients had 
either an ambulatory (n=24,332; 6.23%) or a bed- ridden 
(n=811; 0.21%) body functional status.
Most patients were married (59.5%) with secondary 
education (31.8%), while 54.2% were classified in WHO 
stage III or IV and 34.18% were in the 35–44 years age 
group. The majority of the participants were on first- line 
ART treatment (97.7%), and only a few had confirmed 
tuberculosis infection (1.2%). There were missing data 
on some covariates, including baseline CD4 cell counts 
recorded for only 35.3% of the study participants.
The time- to- event rates for LTFU stratified by baseline 
characteristics are shown in table 2. LTFU rate per 100 
person- years was 5.92 for patients enrolled at district 
and mission hospitals, 6.60 among patients from rural 
health facilities and 17.09 among patients diagnosed with 
tuberculosis.
The cumulative incidence probability (CIP) curve for 
death was lower than the CIP for LTFU as the outcome 
(figure 4A). The LTFU CIP curve increased in the first 3 
years on ART and became steady after that. We observed 
overwhelmingly significant variation between LTFU and 
selected covariates, log- rank p value <0.001. Higher risk 
of LTFU was observed among patients aged 15–24 years 
(figure 4B), females (figure 4C), patients enrolled at 
urban health facilities (figure 4D), tuberculosis- infected 
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patients (figure 4E) and WHO stage I/II patients 
(figure 4F).
LTFU outcome
To determine the possible independent risk factors associ-
ated with LTFU, seven models were fitted, and the results 
are shown in table 3. An additional pictorial view of the 
estimates is provided in the online supplemental appendix 
figure A1 to compare the different model estimates. The 
data had approximately 10% of missing information in 
the explanatory covariates. There was no difference in 
the model estimates between imputed data and complete 
case data (model 1 vs model 2 and model 4 vs model 5). 
Comparing the MLE (model 3) and the BE (model 4) 
models, the estimates were almost similar for most regres-
sion parameters, and inclusion of the individual random 
effects did not improve the model estimates (model 4 
vs model 6). Lastly, adjusting for the competing effects 
of mortality on LTFU showed some significant improve-
ment to the model based on the reduced AIC and BIC 
values compared with the Cox proportional hazard 
model. Hence, the CR model was considered a better fit 
compared with other models, and the interpretation of 
the results will be based on this model.
The multivariable CR model revealed that patient 
factors predicting LTFU included: being enrolled at a 
provincial/referral (AsHR 1.22; 95% CI 1.18 to 1.26) or 
district/mission (AsHR 1.47; 95% CI 1.45 to 1.50) hospi-
tals (reference: PHC), urban sites (AsHR 1.61; 95% CI 
1.59 to 1.63) (reference: rural) and 15–24 years group 
(AsHR 1.19; 95% CI 1.16 to 1.21) (reference: 35–44 
years). We also detected an overwhelming association 
between LTFU and tuberculosis- infected patients (AsHR 
1.53; 95% CI 1.45 to 1.62) (reference: no tuberculosis) 
and a protective effect of LTFU for patients classified in 
WHO stage III or IV (AsHR 0.74; 95% CI 0.73 to 0.75) 
(reference: WHO I/II). Patients who were taking stavu-
dine combination therapy as a first- line ART treatment 
had an increased risk of becoming LTFU relative to 
patients taking TDF+3TC+EFV first- line combination 
therapy, that is, D4T(30)+3TC+NVP (AsHR 5.47; 95% CI 
5.52 to 5.75) and D4T(30)+3TC+EFV (AsHR 7.98; 95% 
CI 6.41 to 9.94). We also observed that patients who initi-
ated ART between 2015 and 2017 had a pronounced risk 
of becoming LTFU compared with patients who enrolled 
between 2012 and 2014 (AsHR 6.02; 95% CI 5.91 to 6.12).
DISCUSSION
This study aims to determine the LTFU rates at different 
healthcare levels after ART services decentralisation 
among ART patients who initiated ART between 2004 and 
2017 and determine other potential independent factors 
using the CR model approach. Our study followed similar 
studies adjusting for the competing effect of mortality 
on LTFU, recognising that those who die are no longer 
at risk of LTFU.27 28 We found the LTFU rate of 5.7 per 
100 person- years, which was lower than that reported in 
Ethiopia of 8.2 per 100 person- years.29 The lower LTFU 
rates in our study put forward the positive impact of 
the decentralised models implemented in Zimbabwe to 
increase patients’ retention in HIV care. However, there 
is still a considerable magnitude of LTFU outcome in 
ART programmes contributing to the ‘leakages’ or attri-
tion of patients within the continuum of care cascade in 
Figure 3 Trend analysis of loss to follow- up outcome among patients receiving ART in Zimbabwe national ART programme on 
a quarterly time scale, 2004–2017.
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(PHC) n=176 253 
(45.1%) (n (%))
District/mission 
hospitals n=192 238 
(49.2%) (n (%))
Provincial/referral 
hospitals n=22 280 
(5.7%) (n (%))
Total
n=390 771 (100%) 
(n (%))
Patient demographics
  Age (years) at ART initiation 15–24 20 314 (11.53) 21 057 (10.95) 2601 (11.67) 43 972 (11.25)
25–34 54 416 (30.87) 58 874 (30.63) 6979 (31.32) 120 269 (30.78)
35–44 59 284 (33.64) 66 418 (34.55) 7875 (35.35) 133 577 (34.18)
45+ 42 239 (23.96) 45 889 (23.87) 4825 (21.66) 92 953 (23.79)
  Degree of urbanisation Rural 113 738 (66.92) 137 380 (73.57) 432 (2.01) 251 550 (66.52)
Urban 56 223 (33.08) 49 348 (26.43) 21 055 (97.99) 126 626 (33.48)
  Sex Female 117 567 (66.70) 124 141 (64.58) 14 136 (63.45) 255 844 (65.47)
Male 58 686 (33.30) 68 097 (35.42) 8144 (36.55) 134 927 (34.53)
  Education status at ART 
initiation
None 3854 (2.19) 4136 (2.15) 227 (1.02) 8217 (2.10)
Primary 33 735 (19.14) 34 062 (17.72) 2248 (10.09) 70 045 (17.92)
Secondary 59 181 (33.58) 58 349 (30.35) 6593 (29.59) 124 123 (31.76)
Tertiary 2921 (1.66) 4423 (2.30%) 1177 (5.28) 8521 (2.18)
Missing 76 562 (43.44) 91 268 (47.48) 12 035 (54.02) 179 865 (46.03)




Single 24 438 (13.87) 24 489 (12.74) 3530 (15.84) 52 457 (13.42)
Married 105 504 (59.86) 113 953 (59.28) 12 935 (58.06) 232 392 (59.47)
Widowed 25 798 (14.64) 30 994 (16.12) 3523 (15.81) 3523 (15.81)
Divorced 13 429 (7.62) 14 732 (7.66) 1677 (7.53) 29 838 (7.64)
Missing 7084 (4.02) 8070 (4.20) 615 (2.76) 15 769 (4.04)
  Calendar time of starting 
ART
2004–2007 6635 (3.76) 8942 (4.65) 2962 (13.29) 18 539 (4.74)
2008–2011 38 990 (22.12) 61 321 (31.85) 7899 (35.45) 108 120 (27.67)
2012–2014 67 759 (38.44) 90 582 (47.12) 9472 (42.51) 167 813 (42.94)
2015–2017 62 869 (35.67) 31 483 (16.38) 1947 (8.74) 96 299 (24.64)
Clinical factors   
  WHO staging at ART 
initiation
I/II 82 203 (46.64) 69 629 (36.22) 7690 (34.52) 159 519 (40.82)
III/IV 79 279 (44.98) 118 113 (61.44) 14 425 (64.74) 211 817 (54.20)
Missing 14 771 (8.38) 4499 (2.34) 165 (0.74) 19 435 (4.97)
  Baseline CD4 (cell/µL) at 
ART initiation
Above 500 4783 (2.71) 4950 (2.57) 601 (2.70) 10 334 (2.64)
351–500 8227 (4.67) 8790 (4.57) 940 (4.22) 17 957 (4.60)
200–350 17 908 (10.16) 24 895 (12.95) 2866 (12.86) 45 669 (11.69)
Below 200 23 796 (13.50) 35 020 (18.22) 4982 (22.36) 63 798 (16.33)
Missing 121 539 (68.96) 118 583 (61.69) 12 891 (57.86) 253 013 (64.75)
  Treatment regimen at the 
time of data extraction
First line 170 662 (98.29) 184 321 (97.37) 20 724 (94.32) 375 704 (97.65)
D4T(30)+3TC+NVP 625 (0.35) 2942 (1.53) 629 (2.82) 4196 (1.07)
D4T(30)+3TC+EFV 42 (0.02) 155 (0.08) 20 (0.09) 217 (0.06)
AZT+3TC+NVP 1349 (0.77) 1933 (1.01) 349 (1.57) 3631 (0.93)
AZT+3TC+EFV 212 (0.12) 425 (0.22) 56 (0.25) 693 (0.18)
TDF+3TC+NVP 6541 (3.71) 16 334 (8.50) 2923 (13.12) 25 798 (6.60)
TDF+3TC+EFV 161 288 (91.51) 162 006 (84.27) 16 628 (4.63) 339 922 (86.99)
Other first lines 3236 (1.84) 3474 (1.81) 428 (1.92) 7138 (1.83)
Second line 2960 (1.68) 4969 (2.58) 1247 (5.60) 9176 (2.35)
  Tuberculosis status at ART 
initiation
Negative 156 072 (88.55) 170 869 (88.88) 20 218 (90.75) 347 159 (88.84)
Positive 2092 (1.19) 2423 (1.26) 301 (1.35) 4816 (1.23)
Not assessed 15 743 (8 93) 16 387 (8.52) 1347 (6.05) 33 477 (8.57)
Missing 2346 (1.33) 2559 (1.33) 414 (1.86) 5319 (1.36)
Continued
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Zimbabwe. This requires continual upscaling of interven-
tions that minimise the LTFU rates and retain patients 
in care since patients who are LTFU are associated with 
increased treatment interruptions that can trigger ART 
treatment defaulting, treatment non- adherence, treat-
ment failure or treatment resistance.30 31
Similar to other studies, LTFU independently increased 
at higher levels of care (provincial and referral (AsHR 
1.22; 95% CI 1.18 to 1.26) and district and mission (AsHR 
1.47; 95% CI 1.45 to 1.50) hospitals) relative to PHC in 
this study.5 This finding supports the fact that decentral-
isation is associated with better patients’ retention in 
care as there are high risks of LTFU rate in higher levels 
of care compared with the PHC facilities. This finding 
supports the assumption that if patients seek care from 
health facilities closer to their homes with cheaper trans-
port cost and less congested hospital environments, there 
is improved patient retention as compared with seeking 
care to faraway health facilities.32 Moreover, the high 
rates of LTFU in secondary and tertiary/quaternary levels 
of care could be explained by ‘silent transfers’ whereby 
patients self- transfer themselves to these decentralised 
PHC facilities based on individual preferences of where 
to seek care, and the system fails to track it. These ‘silent 
transfers’ could be a good indication of the upsurge of 
the decentralisation of services.32 However, such ‘silent 
transfers’ may result in inflated LTFU rates in higher 
levels of care as most these patients would be classified as 
LTFU when in fact they might have self- transferred and 
the patient tracking system is not efficient enough to pick 
such scenarios due to significantly high patients’ volumes 
persisting at these health facilities.5 Similarly, the quar-
terly trend analysis of LTFU rates showed an increase over 
time, peaking in the period when decentralised models 
were implemented. The same issue of ‘silent transfers’ of 
patients to nearer health facilities can also explain this 
trend pattern finding.
On the contrary, not everyone would prefer to seek 
care from these decentralised health facilities. Some 
may intentionally avoid these nearby health facilities to 
conceal their HIV status from the community. These indi-
viduals remain enrolled in faraway health facilities and 
most probably the higher levels of care. These individuals 
may contribute to the observed high rates of LTFU in this 
cohort as they may still face transport cost challenges to 
replenish their ART supplies.33 Moreover, tertiary and 
quaternary levels of care may receive much sicker patients 
with a high risk of death, hoping to get better treatment 
through the healthcare referral system.34 This means 
some of these much ill patients are more likely to become 
LTFU eventually as severe immune deterioration hinders 
one to keep up to date with their treatment replenish-
ments. Earlier studies have also reported that much 
sicker patients with severe immune deterioration are 
more likely to become LTFU compared with those with 
no significant immunodeficiency.35 Other studies have 
also shown that a significant portion of these severely ill 
patients who eventually become LTFU from higher levels 
of care health facilities, if tracked, could be found dead.36 
Our findings put forward that though the decentralisa-
tion uptake might have been taken up by the majority of 
the ART patients and improved patient’s retention in the 
ART programme in overall; those groups of individuals 
who still seek healthcare from the higher levels of care 
are still more at risk of becoming LTFU; hence, interven-
tions that may retain patients in the higher levels of care 
facilities are a priority.
Patients enrolled at urban health facilities had increased 
risk to become LTFU compared with those at rural sites. 
This finding contradicts a study done in Ethiopia whereby 
rural residents had an increased risk of LTFU due to avail-
ability of transport costs, long distances to ART health 
facilities, social stigma as well as low levels of HIV knowl-
edge in these communities.15 However, our study finding 
can be explained by the decentralisation of health facili-
ties to walkable distances in favour of rural residents.4 37 
Mobility of residents in urban areas is disproportionate 
relative to rural residents; hence, most of these LTFU in 
urban areas could be part of the silent transfers to other 
nearer ART health facilities in their relocated areas.
Another interesting finding was high LTFU among 
the 15–24 years group. The adolescent’s group is known 
to be associated with additional intricacy in their HIV 
management due to different types of chronic comorbid-
ities, and this whole complexity may impact on their ART 
outcomes including LTFU.38 39 The high risk of becoming 
LTFU among adolescents can be attributed to structural 
deprivation due to medical and psychological reasons 
that contribute to poor adherence in this subpopulation 
group as a result of becoming LTFU.40 The most common 
Characteristics Categories
Primary healthcare 
(PHC) n=176 253 
(45.1%) (n (%))
District/mission 
hospitals n=192 238 
(49.2%) (n (%))
Provincial/referral 
hospitals n=22 280 
(5.7%) (n (%))
Total
n=390 771 (100%) 
(n (%))
  Body functional status at 
ART initiation
Working 162 710 (92.32) 180 417 (93.85) 20 024 (89.87) 363 151 (92.93)
Ambulatory 11 789 (6.69) 10 454 (5.44) 2089 (9.38) 24 332 (6.23)
Bed ridden 331 (0.19) 452 (0.24) 28 (0.13) 811 (0.21)
Missing 1423 (0.81) 915 (0.48) 139 (0.62) 2477 (0.63)
Missing category refers to information that is unavailable in the dataset for that particular variable.
ART, antiretroviral therapy; AZT, zidovudine; D4T, stavudine; EFV, efavirenz; NVP, nevirapine; 3TC, lamivudine; TDF, tenofovir.
Table 1 Continued
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Table 2 Rates per 100 person- years of LTFU and log- rank tests for ART patients’ baseline characteristics in Zimbabwe 




Rate per 100 
person- years 95% CI of rate





Primary healthcare 34 958 6200 5.6502 5.5913 to 5.7097 <0.001*
District/mission 
hospitals
48 188 8100 5.9169 5.8643 to 5.9700
Provincial/referral 
hospitals
5598 1100 5.0273 4.8973 to 5.1608





15–24 32 790 4500 7.3252 7.2463 to 7.4049 <0.001*
25–34 12 617 1500 8.4301 8.2843 to 8.5785
35–44 27 504 5500 4.9671 4.9087 to 5.0261
45+ 15 833 3900 4.0242 3.9620 to 4.0874
Degree of urbanisation
  
Rural 52 629 10 000 5.2756 5.2307 to 5.3209 <0.001*
Urban 36 115 5500 6.6039 6.5362 to 6.6724
Sex
  
Females 59 695 10 000 5.8703 5.8234 to 5.9175 <0.001*
Male 29 049 5300 5.5063 5.4433 to 5.5700






None 1470 354 4.1582 3.9509 to 4.3762 <0.001*
Primary 14 786 2800 5.3558 5.2702 to 5.4429
Secondary 32 629 4700 6.9961 6.9206 to 7.0725
Tertiary 1803 409 4.4097 4.2108 to 4.6180
Missing 38 056 7300 5.2435 5.1911 to 5.2965






Single 13 078 1900 6.9036 6.7863 to 7.0230 <0.001*
Married 7548 1100 6.6112 6.4637 to 6.7620
Widowed 9375 2900 3.1872 3.1233 to 3.2524
Divorced 55 985 8800 6.3313 6.2790 to 6.3839
Missing 2758 625 4.416 4.2543 to 4.5840





2004–2007 790 1900 0.4255 0.3968 to 0.4562 <0.001*
2008–2011 4572 6900 0.6593 0.6405 to 0.6787
2012–2014 43 565 5300 8.1802 8.1038 to 8.2574
2015–2017 39 817 1300 29.9903 29.6972 to 30.2863




I/II 47 410 5100 9.208 9.1255 to 9.2912 <0.001*
III/IV 38 919 9500 4.0957 4.0552 to 4.1366
Missing 2415 794 3.0432 2.9242 to 3.1671






Above 500 4341 257 16.919 16.4231 to 17.4299 <0.001*
351–500 7614 455 16.7362 16.3645 to 17.1164
200–350 11 556 1700 6.7428 6.6210 to 6.8669
Below 200 15 271 2700 5.7338 5.6436 to 5.8254
Missing 49 962 10 000 4.8245 4.7823 to 4.8669
Treatment regimen at the 









First line 88 050 15 000 5.9066 5.8677 to 5.9457 <0.001*
D4T(30)+3TC+NVP 2685 168 15.9847 15.3914 to 16.6009
D4T(30)+3TC+EFV 141 10 14.7353 12.4932 to 17.3797
AZT+3TC+NVP 448 184 2.4374 2.2218 to 2.6738
AZT+3TC+EFV 158 30 5.3159 4.5484 to 6.2129
TDF+3TC+NVP 9652 1100 9.1737 8.9925 to 9.3586
TDF+3TC+EFV 71 378 13 000 5.371 5.3318 to 5.4106
Other first lines 3588 175 20.559 19.8972 to 21.2429
Second line 694 538 1.29 1.1985 to 1.3908
Continued
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medical barrier that has been found to affect ART adher-
ence include treatment side effects, multiple doses and 
health system dissatisfaction. Research has found that 
ART has improved perinatal HIV infection into a control-
lable disease through optimal ART adherence. This opens 
up an additional challenge among adolescents who were 
prenatally or perinatally infected in the transition stage 
to adult care to experience ART adherence lapses and 
develop worse clinical outcomes as they become LTFU.40 
The transition from the paediatric care to adult care 
would mean changing care providers, absence of youth- 
friendly facilities, tight and hectic schedules, new respon-
sibilities and deprivation of caregiver support for some of 
these adolescents. Some of the social deprivation issues 
among adolescents include inadequate financial support 
to cover transport costs to health facilities for treatment 
refill since this group heavily depends on their care-
givers.41 Some of the social deprivations faced by adoles-
cents include lack of family support as some adolescents 
come from disrupted family structures with depraved 
caregiver–child relationships, fear- perceived HIV- related 
stigma and discrimination to disclose their status.15 41 42
Therefore, this study recommends that policymakers 
should strengthen the social protection support to 
address the complex vulnerability, disadvantages and risks 
faced by HIV- positive adolescents in order to foster resil-
ience among the HIV- positive adolescents population. 




Rate per 100 
person- years 95% CI of rate
Log- rank p 
value





Negative 81 119 14 000 5.9418 5.9010 to 5.9828 <0.001*
Positive 2235 131 17.0906 16.3966 to 17.8141
Not assessed 4188 1400 2.9328 2.8453 to 3.0230
Missing 1202 234 5.1455 4.8627 to 5.4447





Working 81 122 14 000 5.6445 5.6057 to 5.6834 <0.001*
Ambulatory 7059 930 7.5897 7.4147 to 7.7688
Bed ridden 215 26 8.4201 7.3666 to 9.6243
Missing 348 117 2.9723 2.6758 to 3.3015
*Significant at 5%. Missing category refers to information that is unavailable in the dataset for that particular variable.
ART, antiretroviral therapy; AZT, zidovudine; D4T, stavudine; EFV, efavirenz; LTFU, loss to follow- up; NVP, nevirapine; 3TC, lamivudine; 
TDF, tenofovir.
Table 2 Continued
Figure 4 The cumulative incidence probability of mortality and loss to follow- up (A), and Kaplan- Meier curves for loss 
to follow- up stratified by baseline age categories (B), gender (C), level of urbanisation of the health facilities (D), baseline 
tuberculosis infection status (E) and baseline WHO clinical stages for ART patients from the Zimbabwe national ART programme 
electronic patient monitoring data, 2004–2017. ART, antiretroviral therapy.
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social deprivations faced by adolescents through poverty 
reduction and economic development, improved access 
to healthcare, access to health services, reduced stigma 
and discrimination and improved caregiver psychosocial 
and physical well- being. Another recommendation is the 
use of health facility- based peer- supporters programmes 
for adolescents to improve ART adherence and, ulti-
mately, viral suppression.43 44 The peer support activities 
involve peer- to- peer counselling, peer support groups 
and treatment buddy programmes among adolescents 
with the aim of ART adherence and ultimately achieving 
viral suppression, reducing the HIV- related illnesses 
among adolescents. As adolescents may exit the HIV care 
through becoming LTFU or withdrawals due to transi-
tion adjustments challenges from paediatric care to adult 
care, an early multidisciplinary and developmentally suit-
able transition preparedness mechanism is an alternative. 
The mechanism should be a comprehensive package 
addressing inherent adolescents’ health issues like cogni-
tive health, ART adherence, stigma, disclosure and socio-
economic issues.38 44 Besides, a simple regimen, directly 
observed therapy and technological interventions like 
cellphone reminders have been found to increase ART 
adherence in adolescents.
We observed an overwhelming association of tuber-
culosis infection and becoming LTFU that concurs with 
an earlier study that reported that the risk of becoming 
LTFU was two times more likely in HIV patients with 
tuberculosis infection compared with those who did 
not have tuberculosis.29 This finding can be explained 
by overlapping toxicity of HIV and tuberculosis drugs, 
leading to adverse reactions that have a direct conse-
quence of becoming LTFU.29 Therefore, a push towards 
integrated care of HIV and tuberculosis service delivery 
would elevate HIV uptake and tuberculosis screening 
and reduce travel inconveniences on patients.34 45 Also, 
tuberculosis treatment before ART initiation reduces the 
risk to LTFU42; hence, it is profound to increase efforts 
in tuberculosis screening and treatment of patients with 
HIV. However, issues around tuberculosis drug resis-
tance cannot be ignored. Nowadays, HIV studies also 
consider information on non- communicable diseases 
like cancer, diabetes and hypertension; however, 
this information was missing from this current study 
database.
We also detected that patients classified in WHO stage 
III or IV were less likely to become LTFU relative to those 
classified in WHO stage I or II. However, our finding 
contradicts with earlier studies that have reported that 
experiencing a severe AIDS- defining ailment was associ-
ated with reduced risk of becoming LTFU.27 46 Our study 
finding may put forward the fact that there could have 
been an upsurge of health- seeking behaviour among 
patients with advanced WHO clinical stages in this data-
base cohort or this finding could be attributed to expan-
sions of community awareness through health promotion 
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Strengths and weaknesses of this study
This study highlights several strengths. A regularisation 
variable selection technique was used to identify important 
covariates. The lasso model shrinks the variable coeffi-
cient to zero and produces a simpler model that can be 
interpreted easily. For the survival analysis, the standard 
Cox regression model overestimated the risk in the pres-
ence of CRs, and we used the Fine and Gray CR model 
instead.47 Ignoring CRs alters the probabilities of occur-
rence of the outcome giving biased estimates. Standard 
survival methods normally used in many studies censor 
the CR; however, this is improper because those who 
have died can no longer become LTFU. Such analysis will 
either overestimate or underestimate the risk ratios. We 
also used individual data that enabled exploration and 
adjustment for patient- level covariates associated with the 
outcome to get robust information on the ART outcome 
patterns as compared with aggregated data.33 48 The study 
follow- up period was relatively long (13 years), and the 
data came from all the 10 provinces in Zimbabwe without 
restriction to specific geographical areas. The data repre-
sented quaternary, tertiary, secondary and primary health 
facilities from private and public sectors. This makes our 
results generalisable to the whole of Zimbabwe since the 
data reflect a true representation of all PLWHIV in the 
country. To the best of our knowledge, this study has used 
one of the largest datasets to analyse adult ART outcomes 
at the patient level.
Our study results should be inferred in light of some 
limitations. Missing data was of concern, particularly 
to those variables that influence LTFU like viral load 
and CD4 cell count in addition to non- communicable 
diseases comorbidities. The presence of missing data 
could be explained by poor documentation of informa-
tion34 or limited access to the point of care machines for 
viral load and CD4 cell counts measurements.4 49 50 The 
missing patterns for some covariates like viral load and 
CD4 cell count measurements were likely to be informa-
tive and missing not at random since differentiated care 
monitoring approach was used in some years covered 
by this study.51 Therefore, to maintain sufficient power, 
covariates with a high percentage of missing observa-
tions were excluded at the multivariable analysis stage. 
In future, we recommend that the data clerks should be 
trained on the importance of capturing full information 
and to the programme managers to consider expanding 
the HIV routine data collection tool to capture non- 
communication diseases conditions of the HIV patients. 
The sociodemographic and clinical characteristics in the 
database were only taken at baseline or last observed at 
the time of data extraction; hence, we could not incor-
porate the time dependency of some covariates. We also 
acknowledge that there could be differential misclassifi-
cation of the LTFU outcome in this study in the sense that 
some of those recorded as LTFU may be ‘silent transfers’ 
who have enrolled in a different health facility as a result 
of ART decentralisation and have been given a different 
unique identifier number; hence, this might have biased 
our LTFU estimates in this study. There is also a possi-
bility of participant selection bias since we only consid-
ered patients whose information as captured through 
the ePMS; as a result, the reported findings could be 
systematically different from those patients not included. 
However, it is of paramount importance to note that the 
dataset used was huge, and representation of the health 
facilities in Zimbabwe was reflected; hence, our findings 
could be generalised to all ART services health facilities 
in Zimbabwe.
While our findings for the common predictors of LTFU 
may be comparable with earlier studies conducted in sub- 
Saharan African region, we had also hypothesised that 
those ART patients who enrolled around 2008 would have 
a higher risk of becoming LTFU. This was done taking 
note of the hyperinflation that occurred in Zimbabwe 
during the part of the study period under review. The 
economic turmoil was allied to the increased mass depar-
ture of qualified health professionals and scarcities of 
vital medical supplies in health facilities.21 22 Despite this 
situation, we detected a protective effect of becoming 
LTFU between 2008 and 2011 in this study. This could be 
explained by the support the country received through 
Global Fund,4 and ART sites increased from 282 sites in 
2008 to 1006 in 2012.37 For further studies, we recommend 
the use of time- varying covariates like regimen type, CD4 
cell counts, WHO stages and viral load measurements 
and the use of spatial analysis of ART outcome to iden-
tify high burdened regions that the policymakers may use 
to allocate resources, especially in resource- constrained 
settings.
Conclusion
The results from this current study using the data span-
ning over 13 years agree with the evident decline of the 
HIV incidence and prevalence in Zimbabwe, and the 
findings are comparable with similar HIV studies’ find-
ings, even from Demographic Health Survey.52 Our 
results indicate that patient retention in care is still a 
drawback in HIV prevention and control. Policymakers 
and programme managers should come up with strat-
egies to retain patients on ART. These strategies may 
include increased patient surveillance and strengthened 
patient tracing mechanisms to reduce LTFU at health 
facilities, strengthened community- based caregiver and 
peer support,14 and nutritional aid support especially for 
adolescents and young adults (15–34 years). In addition, 
interventions that minimise ‘leakages’ in the HIV treat-
ment cascade including the use of ART adherence clubs 
to reduce ART resistance53 and advice on sexual absti-
nence should remain the cornerstone of HIV preven-
tion and control. As much as most of the observed LTFU 
outcome at higher levels of care (district, provincial and 
central hospitals) could be ‘silent transfers’, most patients 
who become LTFU are likely to have poor ART adher-
ence if not dead. Poor ART adherence leads to poor viral 
suppression that affects achieving the third 90% UNAIDS 
targets, which state that 90% of those patients on ART 
14 Matsena Zingoni Z, et al. BMJ Open 2020;10:e036136. doi:10.1136/bmjopen-2019-036136
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should be virally suppressed. Clinicians should provide 
continual educational support on the importance of ART 
adherence to increase life expectancy among the HIV 
population and other benefits of ART. More important 
than not meeting the UNAIDS targets is the impact that 
poor viral suppression has on patients’ health.
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